adra1b-protein

ADRA1B Protein — Alpha-1B Adrenergic Receptor

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ADRA1B Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>ADRA1B, Alpha-1B Adrenergic Receptor</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[ADRA1B](https://www.ncbi.nlm.nih.gov/gene/147)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P15888](https://www.uniprot.org/uniprot/P15888)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~50-60 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane, caveolin-rich domains</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Class A GPCR, α1-adrenergic family</td></tr>
<tr><td><strong>Ligand</strong></td><td>Norepinephrine, epinephrine</td></tr>
<tr><td><strong>Signal Transduction</strong></td><td>Gq/11 protein, PLCβ, Ca²⁺</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">14 edges</a></td>
</tr>
</table>
</div>

Overview

ADRA1B Protein — Alpha-1B Adrenergic Receptor

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ADRA1B Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>ADRA1B, Alpha-1B Adrenergic Receptor</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[ADRA1B](https://www.ncbi.nlm.nih.gov/gene/147)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P15888](https://www.uniprot.org/uniprot/P15888)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~50-60 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane, caveolin-rich domains</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Class A GPCR, α1-adrenergic family</td></tr>
<tr><td><strong>Ligand</strong></td><td>Norepinephrine, epinephrine</td></tr>
<tr><td><strong>Signal Transduction</strong></td><td>Gq/11 protein, PLCβ, Ca²⁺</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">14 edges</a></td>
</tr>
</table>
</div>

Overview

The Alpha-1B Adrenergic Receptor (ADRA1B) is a G protein-coupled receptor (GPCR) that mediates the effects of norepinephrine and epinephrine on target tissues. It belongs to the α1-adrenergic receptor subfamily, which includes ADRA1A (α1A), ADRA1B (α1B), and ADRA1D (α1D) subtypes. ADRA1B plays important roles in cardiovascular function, smooth muscle contraction, neurotransmission, and has emerged as a significant player in neurodegenerative disease pathogenesis [1].[@c2009]

In the central nervous system (CNS), ADRA1B is involved in arousal, attention, stress responses, and cognitive function. The receptor is widely distributed in brain regions critical for memory and executive function, including the [prefrontal cortex](/brain-regions/prefrontal-cortex), [hippocampus](/brain-regions/hippocampus), and [hypothalamus](/brain-regions/hypothalamus). Dysregulation of α1-adrenergic signaling has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and vascular cognitive impairment [2].[@mj2000]

The noradrenergic system, which uses norepinephrine (NE) as its primary neurotransmitter, is severely affected in neurodegenerative diseases. The locus coeruleus (LC), the main source of norepinephrine in the brain, undergoes significant degeneration in both AD and PD.[@j2003] This degeneration leads to widespread dysregulation of adrenergic signaling, including ADRA1B-mediated pathways, contributing to cognitive decline, neuropsychiatric symptoms, and autonomic dysfunction [3].

Structure

ADRA1B has the canonical seven-transmembrane domain structure characteristic of Class A GPCRs:

Transmembrane Domains

• Seven α-helices: TM1-TM7 cross the lipid bilayer at angles of ~20-30°
• Conserved sequence motifs: Characteristic of rhodopsin-like GPCRs
• DRY motif at the boundary of TM3 and intracellular loop 2
• NPxxY motif in TM7
• CWxP motif in TM6
• Orthosteric binding pocket: Located deep within the transmembrane bundle, binds catecholamines (norepinephrine, epinephrine)
• Binding site architecture: Conserved aspartic acid in TM3 (Asp125) serves as a primary anchor for the amine group of catecholamines

Extracellular Domain

• N-terminal tail: Short extracellular sequence (approximately 30 amino acids)
• Loop regions: Three extracellular loops (ECL1-ECL3)
• ECL1: ~15-20 amino acids, contains conserved cysteine for disulfide bond
• ECL2: Largest extracellular loop, ~40-50 amino acids
• ECL3: Shortest, ~10-15 amino acids

Intracellular Domain

• C-terminal tail: Contains serine/threonine phosphorylation sites (~50 amino acids)
• G protein coupling region: Located in intracellular loops 2 and 3
• Third intracellular loop: Critical for Gq/11 protein specificity

Structural Features Unique to ADRA1B

ADRA1B exhibits subtype-specific structural characteristics:

• Ligand binding selectivity: The binding pocket differs from ADRA1A and ADRA1D
• G protein coupling: Highly selective for Gq/11 over other G proteins
• Palmitoylation: C-terminal cysteine for membrane anchoring
• Glycosylation: N-terminal N-linked glycosylation sites

Crystal Structure and Modeling

Recent advances in GPCR structural biology have enabled detailed understanding of α1-adrenergic receptor structure:

• Cryo-EM structures: High-resolution structures of related α1 receptors
• Molecular dynamics: Simulations revealing ligand-induced conformational changes
• Allosteric sites: Identification of potential allosteric modulatory sites

Normal Function

Signal Transduction Cascade

ADRA1B activates the Gq/11 signaling pathway through a well-characterized cascade [4]:

Physiological Roles

Cardiovascular System

• Vascular tone: Vasoconstriction in peripheral vasculature, particularly in skin, splanchnic, and renal beds
• Blood pressure regulation: Contributes to maintenance of blood pressure through alpha-adrenergic vasoconstriction
• Cardiac function: Positive inotropic effects, though less prominent than β-adrenergic effects

Smooth Muscle

• Bladder: Contraction of detrusor muscle, regulation of urinary function
• Gastrointestinal tract: Modulation of intestinal motility and tone
• Uterus: Uterine smooth muscle contraction
• Pupil: Radial muscle contraction causing mydriasis (pupillary dilation)

Central Nervous System

• Arousal and wakefulness: Noradrenergic signaling promotes cortical activation
• Attention: Modulation of attentional processes, particularly in prefrontal cortex
• Stress response: Activation of sympathetic nervous system via hypothalamic-pituitary-adrenal (HPA) axis modulation
• Cognitive function: Influences working memory and executive function
• Thermoregulation: Brown adipose tissue thermogenesis

Expression Pattern

ADRA1B is expressed in multiple tissue types [5]:

Peripheral Tissues

• Liver: Hepatocyte expression, affects gluconeogenesis
• Kidney: Renal vasculature and tubules
• Heart: Myocardial cells, coronary vasculature
• Vasculature: Arterial and venous smooth muscle
• Adipose tissue: White and brown adipose tissue

Central Nervous System

• Cerebral cortex: Layer 5 pyramidal neurons
• Hippocampus: CA1 and CA3 regions, dentate gyrus
• Hypothalamus: Paraventricular nucleus, supraoptic nucleus
• Amygdala: Central and basolateral nuclei
• Locus coeruleus: Noradrenergic cell bodies
• Cerebellum: Purkinje cells, deep cerebellar nuclei

Glial Cells

• Astrocytes: Modulation of astrocyte function and blood-brain barrier
• Microglia: Regulation of microglial activation and neuroinflammation

G Protein Coupling Specificity

ADRA1B exhibits high selectivity for Gq/11 proteins:

• Gαq family: Primary coupling to Gq, G11, G14, G16
• Gβγ subunits: Also released upon activation, modulate additional effectors
• Alternative coupling: Can couple to Gz in certain cell types
• Bias signaling: Ligand-directed signaling (biased agonism) possible

Role in Neurodegeneration

Alzheimer's Disease

ADRA1B plays a multifaceted role in Alzheimer's disease pathogenesis [6]:

Vascular Dysfunction

• Cerebral autoregulation: Impaired α1-adrenergic control of cerebral blood flow
• Blood-brain barrier (BBB): ADRA1B activation affects BBB permeability
• Angiogenesis: Dysregulated vascular endothelial growth factor signaling
• Amyloid angiopathy: Interaction with cerebral amyloid angiopathy (CAA)

Neuroinflammation

• Microglial activation: α1-adrenergic signaling promotes pro-inflammatory microglial phenotype
• Cytokine production: Increased IL-1β, TNF-α, IL-6 release
• Neuroinflammation amplification: Chronic noradrenergic dysfunction creates inflammatory feed-forward loop
• Astrocyte regulation: Modulation of astrocyte reactivity and function

Cognitive Dysfunction

• Working memory: Prefrontal cortical α1-adrenergic modulation of working memory
• Attention: Noradrenergic attention system dysregulation
• Synaptic plasticity: Effects on long-term potentiation (LTP) and memory consolidation
• Sleep-wake cycle: Disrupted norepinephrine signaling affects sleep architecture

Therapeutic Implications

α1-adrenergic modulation represents a therapeutic target in AD:

• α1 antagonists: Prazosin shows promise in preclinical and clinical studies
• Peripheral vs. central effects: Challenge of achieving central effects without peripheral side effects
• Combination therapy: Potential for combined α1 and β-adrenergic modulation
• Timing considerations: Optimal intervention in disease course

Parkinson's Disease

ADRA1B contributes to several aspects of Parkinson's disease [8]:

Autonomic Dysfunction

• Orthostatic hypotension: α1-adrenergic dysregulation contributes to blood pressure dysregulation
• Urinary dysfunction: Bladder overactivity related to noradrenergic signaling
• Gastrointestinal dysmotility: Colonic dysfunction in PD
• Sexual dysfunction: Autonomic involvement in PD

Neuroprotection

• Dopaminergic neuron survival: Noradrenergic modulation of nigral neuron survival
• Oxidative stress: Modulation of oxidative stress responses
• Mitochondrial function: Effects on mitochondrial dynamics and function
• Neuroinflammation: Anti-inflammatory vs. pro-inflammatory effects

L-DOPA-Induced Dyskinesia

• Dyskinesia development: Role of noradrenergic signaling in LID pathophysiology
• α1-adrenergic antagonists: Potential for reducing dyskinesia severity
• Combined dopaminergic and noradrenergic targeting: Novel therapeutic strategies

Vascular Cognitive Impairment

ADRA1B plays a significant role in vascular cognitive impairment (VCI):

Cerebral Autoregulation

• Impaired blood flow regulation: Dysfunctional α1-adrenergic control
• White matter damage: Hypoperfusion-related white matter lesions
• Microinfarcts: Contribution to microvascular pathology

Ischemic Injury

• Stroke recovery: Role in post-stroke rehabilitation
• Neuroprotection: Potential for protecting against ischemic damage
• Angiogenesis: Effects on post-ischemic recovery

Mixed Dementia

• AD/Vascular overlap: Interaction between vascular pathology and AD
• Therapeutic targeting: Modulating cerebral vasculature

Stroke and Recovery

ADRA1B affects stroke pathophysiology and recovery:

Acute Phase

• Cerebral vasoconstriction: Role in acute blood flow responses
• Blood-brain barrier: Effects on BBB disruption
• Excitotoxicity: Interaction with glutamate excitotoxicity

Recovery Phase

• Neurogenesis: Effects on adult neurogenesis
• Angiogenesis: Role in post-stroke vascular remodeling
• Functional recovery: Modulation of rehabilitation outcomes

Neuroprotection Mechanisms

ADRA1B signaling can be neuroprotective through [9]:

• Anti-apoptotic effects: PKC-mediated pro-survival signaling
• Antioxidant responses: Activation of Nrf2 pathway
• Heat shock protein induction: HSP70 and other protective proteins
• Autophagy modulation: Regulation of autophagic processes

Therapeutic Targeting

Drug Development

| Drug Class | Mechanism | Example | Clinical Use | Status |
|------------|-----------|---------|--------------|--------|
| Antagonists | Block receptor | Prazosin | Hypertension, PTSD | Approved |
| Partial agonists | Weak activation | Midodrine | Orthostatic hypotension | Approved |
| Selective antagonists | α1B-selective | Terazosin | BPH | Approved |
| Inverse agonists | Constitutive activity | -- | Research | Preclinical |
| Allosteric modulators | Bind allosteric site | -- | Research | Preclinical |

Clinical Applications

Approved Indications

Hypertension:

• Prazosin, doxazosin, terazosin: First-generation α1 blockers
• Effect on blood pressure: Reduction of peripheral vascular resistance
• Side effects: Orthostatic hypotension, reflex tachycardia

• Terazosin, doxazosin: α1-adrenergic blockade in prostate
• Effect: Reduced urinary outlet obstruction
• Additional benefit: May improve lipid profile

• Prazosin: Reduces trauma-related nightmares and sleep disturbance
• Mechanism: Central α1-adrenergic blockade
• Evidence: Multiple clinical trials support efficacy

• Midodrine: Direct α1-adrenergic agonist
• Effect: Increase peripheral vascular tone
• Use: Neurogenic orthostatic hypotension

Off-Label Uses

Alzheimer's Disease:

• Prazosin: Investigated for cognitive enhancement
• Evidence: Mixed results from clinical trials
• Challenge: Central vs. peripheral effects

• Doxazosin, terazosin: Potential neuroprotective effects
• Evidence: Preclinical and some clinical data
• Consideration: Autonomic symptom management

CNS Applications in Development

Cognitive Enhancement

• Target: Prefrontal cortical ADRA1B
• Approach: Selective antagonists or biased agonists
• Challenge: Achieving central activity without peripheral effects

Neuroprotection

• Target: Multiple pathways including anti-apoptotic, antioxidant
• Approach: Modulation of ADRA1B signaling
• Potential: Disease-modifying effects

Stroke Recovery

• Target: Cerebral vasculature and neurogenesis
• Approach: α1-adrenergic modulation
• Evidence: Preclinical models show promise

Pharmacokinetics

• Absorption: Well-absorbed orally
• Distribution: Variable CNS penetration (prazosin > terazosin)
• Metabolism: Hepatic metabolism (CYP enzymes)
• Elimination: Renal and hepatic clearance

Adverse Effects

• Orthostatic hypotension: Most common, especially initial dosing
• Reflex tachycardia: Due to vasodilation
• Sexual dysfunction: Erectile dysfunction
• Central effects: Drowsiness, fatigue, headache

Animal Models

Knockout Models

ADRA1B knockout mice:

• Cardiovascular: Hypotension, reduced pressor response
• Smooth muscle: Impaired contractile responses
• Behavioral: Altered stress response, anxiety-like behavior
• Metabolic: Altered energy homeostasis

Transgenic Models

• Overexpression studies: Effects on blood pressure, anxiety
• Conditional knockout: Tissue-specific deletion
• Humanized models: Expressing human ADRA1B

Disease Models

• Hypertension models: DOCA-salt, spontaneous hypertension
• Stroke models: Middle cerebral artery occlusion (MCAO)
• AD models: APP/PS1, 5xFAD with ADRA1B modulation
• PD models: MPTP, 6-OHDA with ADRA1B studies

Genetic Variation

Polymorphisms

• Coding variants: Affect receptor function and pharmacology
• Promoter variants: Influence expression levels
• Linkage disequilibrium: Haplotype structure
• Ethnic variation: Different allele frequencies across populations

Clinical Implications

• Drug response: Variability in response to α1 blockers
• Disease risk: Potential association with cardiovascular disease
• Pharmacogenomics: Personalized medicine applications

Biomarkers

Peripheral Biomarkers

• Plasma NE levels: Reflect sympathetic activity
• ADRA1B expression: On peripheral blood cells
• Genetic markers: SNP associations

CNS Biomarkers

• Imaging: PET ligands for α1-adrenergic receptors
• CSF markers: Limited evidence
• Functional measures: Blood pressure responses

Research Directions

Biomarkers

• Peripheral ADRA1B: As sympathetic activity marker
• Genetic variants: Predict drug response
• Expression studies: In neurodegenerative disease

Gene Therapy

• Viral vector delivery: Target CNS ADRA1B
• CRISPR approaches: Edit ADRA1B gene
• RNA interference: Reduce ADRA1B expression

Structural Studies

• Cryo-EM: High-resolution structure determination
• Allosteric sites: Novel drug binding sites
• Dynamics: Conformational changes upon activation

Novel Therapeutics

• Biased agonists: Signaling pathway-selective compounds
• Peripheral restrictions: Limit CNS side effects
• Combination approaches: Multi-target strategies

See Also

• [Proteins Index](/proteins)
• [Genes Index](/genes)
• [ADRA1B Gene](/genes/adra1b)
• [Adrenergic Receptors](/proteins)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Noradrenergic Signaling](/mechanisms/noradrenergic-signaling-neurodegeneration)
• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• [Microglia](/cell-types/microglia-neuroinflammation)
• [Neuroinflammation](/cell-types/microglia-neuroinflammation)

External Links

• [UniProt P15888](https://www.uniprot.org/uniprot/P15888)
• [NCBI Gene ADRA1B](https://www.ncbi.nlm.nih.gov/gene/147)
• [IUPHAR Database](https://www.guidetopharmacology.org/record/GPCR/1489)
• [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000170156-ADRA1B)
• [GeneCards ADRA1B](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRA1B)

References